問題詳情

8.有關免疫檢查點抑制劑（immune checkpoint inhibitor），下列何者錯誤？
(A)有針對腫瘤或免疫T細胞上受體作用之抑制劑
(B)avelumab與pembrolizumab皆可阻斷PD-1與PD-L1的結合
(C)比起傳統化療藥物例如alkylating agents副作用小
(D)belimumab可有效的阻斷T細胞上CD2的活化

參考答案

答案：D
難度：困難0.363636
統計：A(3),B(4),C(0),D(4),E(0)

用户評論

【用戶】GE

【年級】大一下

【評論內容】belimumab可有效的阻斷B細胞的活化，可用來治療autoantibody-positive systemic lupus erythematosus (SLE)Ref. Basic and Clinical Pharmacology, 14th Edition

【用戶】GE

【年級】大一下

【評論內容】belimumab可有效的阻斷B細胞的活化，可用來治療autoantibody-positive systemic lupus erythematosus (SLE)Ref. Basic and Clinical Pharmacology, 14th Edition

【用戶】如果詳解被鎖找 北醫王瑞賢

【年級】高一上

【評論內容】【解題】整理自Basic & clinical pharmacology p.994Belimumab1.機轉：B細胞調節者：抑制B細胞活化2.適應症：自體免疫抗體(+)也接受標準治療之 systemic lupus erythematosus (SLE)患者3.副作用：嘔吐、腹瀉、呼吸道感染【附上原文】Belimumab is a Mab that inhibits B cell activating factor, also known as B lymphocyte stimulator, preventing B cells from being stimulated. It is approved for treatment of adults with active, autoantibody-positive systemic lupus erythematosus (SLE) who are also receiving standard therapy. 【延伸學習 &國考複習】1.抑制淋巴結CTLA-4：Ipilimumab2. 結合T細胞上PD-1：Nivolumab、...